We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NorthSea Therapeutics

News List

NorthSea Therapeutics secures funding to develop NASH drug pharmaceutical-technology
December 14, 2017
Dutch biotech firm NorthSea Therapeutics has secured a €25m Series A funding to develop a structurally engineered fatty acid (SEFA), icosabutate, for treating non-alcoholic steatohepatitis (NASH).
NorthSea Therapeutics Secures €25 Million Funding for Clinical Development of Promising NASH Drug b3cnewswire
December 13, 2017
NorthSea Therapeutics B.V. a newly established Dutch biotech company, announced today the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment